Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes. Issue 5 (5th March 2021)
- Record Type:
- Journal Article
- Title:
- Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes. Issue 5 (5th March 2021)
- Main Title:
- Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes
- Authors:
- Taskinen, Marja‐Riitta
Björnson, Elias
Matikainen, Niina
Söderlund, Sanni
Pietiläinen, Kirsi H.
Ainola, Mari
Hakkarainen, Antti
Lundbom, Nina
Fuchs, Johannes
Thorsell, Annika
Andersson, Linda
Adiels, Martin
Packard, Chris J.
Borén, Jan - Abstract:
- Abstract: Aim: To elucidate the impact of liraglutide on the kinetics of apolipoprotein (apo)B48‐ and apoB100‐containing triglyceride‐rich lipoproteins in subjects with type 2 diabetes (T2D) after a single fat‐rich meal. Materials and Methods: Subjects with T2D were included in a study to investigate postprandial apoB48 and apoB100 metabolism before and after 16 weeks on l.8 mg/day liraglutide ( n = 14) or placebo ( n = 4). Stable isotope tracer and compartmental modelling techniques were used to determine the impact of liraglutide on chylomicron and very low‐density lipoprotein (VLDL) production and clearance after a single fat‐rich meal. Results: Liraglutide reduced apoB48 synthesis in chylomicrons by 60% ( p < .0001) and increased the triglyceride/apoB48 ratio (i.e. the size) of chylomicrons ( p < .001). Direct clearance of chylomicrons, a quantitatively significant pathway pretreatment, decreased by 90% on liraglutide ( p < .001). Liraglutide also reduced VLDL1 ‐triglyceride secretion ( p = .017) in parallel with reduced liver fat. Chylomicron‐apoB48 production and particle size were related to insulin sensitivity ( p = .015 and p < .001, respectively), but these associations were perturbed by liraglutide. Conclusions: In a physiologically relevant setting that mirrored regular feeding in subjects with T2D, liraglutide promoted potentially beneficial changes on postprandial apoB48 metabolism. Using our data in an integrated metabolic model, we describe how the actionAbstract: Aim: To elucidate the impact of liraglutide on the kinetics of apolipoprotein (apo)B48‐ and apoB100‐containing triglyceride‐rich lipoproteins in subjects with type 2 diabetes (T2D) after a single fat‐rich meal. Materials and Methods: Subjects with T2D were included in a study to investigate postprandial apoB48 and apoB100 metabolism before and after 16 weeks on l.8 mg/day liraglutide ( n = 14) or placebo ( n = 4). Stable isotope tracer and compartmental modelling techniques were used to determine the impact of liraglutide on chylomicron and very low‐density lipoprotein (VLDL) production and clearance after a single fat‐rich meal. Results: Liraglutide reduced apoB48 synthesis in chylomicrons by 60% ( p < .0001) and increased the triglyceride/apoB48 ratio (i.e. the size) of chylomicrons ( p < .001). Direct clearance of chylomicrons, a quantitatively significant pathway pretreatment, decreased by 90% on liraglutide ( p < .001). Liraglutide also reduced VLDL1 ‐triglyceride secretion ( p = .017) in parallel with reduced liver fat. Chylomicron‐apoB48 production and particle size were related to insulin sensitivity ( p = .015 and p < .001, respectively), but these associations were perturbed by liraglutide. Conclusions: In a physiologically relevant setting that mirrored regular feeding in subjects with T2D, liraglutide promoted potentially beneficial changes on postprandial apoB48 metabolism. Using our data in an integrated metabolic model, we describe how the action of liraglutide in T2D on chylomicron and VLDL kinetics could lead to decreased generation of remnant lipoproteins. … (more)
- Is Part Of:
- Diabetes, obesity & metabolism. Volume 23:Issue 5(2021)
- Journal:
- Diabetes, obesity & metabolism
- Issue:
- Volume 23:Issue 5(2021)
- Issue Display:
- Volume 23, Issue 5 (2021)
- Year:
- 2021
- Volume:
- 23
- Issue:
- 5
- Issue Sort Value:
- 2021-0023-0005-0000
- Page Start:
- 1191
- Page End:
- 1201
- Publication Date:
- 2021-03-05
- Subjects:
- dyslipidaemia -- GLP‐1 analogue -- type 2 diabetes
Diabetes -- Periodicals
Obesity -- Periodicals
Metabolism -- Disorders -- Periodicals
Clinical pharmacology -- Periodicals
616.462 - Journal URLs:
- http://www.blackwellpublishing.com/journal.asp?ref=1462-8902&site=1 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1463-1326 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/dom.14328 ↗
- Languages:
- English
- ISSNs:
- 1462-8902
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3579.601970
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22769.xml